Scratchpad for information gleaned from articles and rabbit-holes from March 2020, starting in the quarantine and lockdown period of damage limitation for the coronavirus.
🇬🇧🇪🇺aluvia 🇺🇸kaletra (lopinavir + coronavirus) developed at University of Chicago by Abbott Laboratories🇺🇸.
🇺🇸remdesivir—an experimental drug that has proved effective against the SARS and MERS viruses in vitro. Manufactured by Gilead Sciences🇺🇸.
🇨🇿tenofovir antiviral drug, based on compounds co-discovered by Erik De Clercq🇧🇪funded by Gilead Sciences🇺🇸.
🇧🇪Erik De Clercq, emeritus professor of medicine at KU Leuven in Belgium.
LABORATORIES + SOURCES
Clinical trials in progress
- The US National Institute of Allergy and Infectious Disease (NIAID) collaborated with Moderna to develop an RNA vaccine matching a spike of the coronavirus surface. In February 2020, NIAID registered a Phase 1 safety clinical trial of the vaccine, called mRNA-1273, open for recruitment in Seattle, WA. On 16 March 2020, the human study began.
- In Australia, the University of Queensland is investigating the potential of a molecular clamp vaccine that would genetically modify viral proteins in order to stimulate an immune reaction.
- In Canada, the International Vaccine Centre (VIDO-InterVac), University of Saskatchewan, received federal funding to work on a vaccine, aiming to start non-human animal testing in March 2020 and human testing in 2021.
- The Chinese Center for Disease Control and Prevention
- University of Hong Kong
- Around 29 January 2020, Janssen Pharmaceutical Companies began work on developing a vaccine. Janssen is codeveloping an oral vaccine with its biotechnology partner, Vaxart. On 18 March 2020, Emergent BioSolutions announced a manufacturing partnership with Vaxart to develop the vaccine.
- Inovio Pharmaceuticals is developing a DNA-based vaccination in collaboration with a Chinese firm, planning human clinical trials in the summer of the Northern Hemisphere of 2020.
- The Jenner Institute of the University of Oxford developed a vaccine candidate based on a chimp adenovirus vector and signed a manufacturing contract with Advent. They plan to start animal trials at Porton Down in March 2020 and human safety trials the following month.
- Washington University in St. Louis
- On 5 March 2020, the United States Army Medical Research and Materiel Command at Fort Detrick and the Walter Reed Army Institute of Research in Silver Spring, both in western Maryland, announced they were working on a vaccine.
- University of Copenhagen, with funding from the European Commission
- Emergent Biosolutions teamed with Novavax Inc. in the development and manufacture of a vaccine. The partners plan on preclinical testing and a Phase I clinical trial by July 2020.
- On 10 March 2020, the Oak Ridge National Laboratory and the University of Tennessee announced they had used the supercomputer Summit to investigate a model of the virus’ spike protein and identify 77 drug compounds that could be used in vaccine candidates. On 19 March, CNN reported that the researchers are in the process of updating the model.
- On 12 March 2020, India’s Health Ministry announced they are working with 11 isolates and that even on a fast track it would take at least around one-and-a-half to two years to develop a vaccine.
- On 16 March 2020, the European Commission offered an €80 million investment in CureVac, a German biotechnology company, to develop a mRNA vaccine.
- On 17 March 2020, American pharmaceutical company Pfizer announced a partnership with German company BioNTech to jointly develop a mRNA-based vaccine.